Antipodes Partners’s Genmab GMAB Stock Holding History

Antipodes Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-185,698	Closed	-$5.91M	–	72
2023 Q4	$5.91M	Buy	+185,698	New	+$5.83M	0.18%	43

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodes Partners's GMAB Position: Q1 2024 in Review

Antipodes Partners sold out of Genmab (GMAB) in Q1 2024, closing a stake of 185,698 shares — an estimated $5.91M sold.

Antipodes Partners first reported a position in GMAB in Q4 2023 and held it in 1 quarter. The position peaked at $5.91M in Q4 2023. 227 funds tracked by Wall St. Rank hold GMAB as of Q1 2024.

Antipodes Partners reported no remaining Genmab position as of Q1 2024 after selling out during the quarter.
Antipodes Partners sold 185,698 Genmab shares in Q1 2024, an estimated $5.91M.
Antipodes Partners first reported a position in Genmab in Q4 2023 and held it in 1 quarter.
Antipodes Partners's Genmab position peaked at $5.91M in Q4 2023.
227 funds tracked by Wall St. Rank held Genmab as of Q1 2024.

Based on Antipodes Partners's 13F filing for Q1 2024, filed 7 May 2024.